title: [Cardiovascular complications with cyclooxygenase inhibitors : Myths and facts].
abstract: During the last decade there have been nearly 10,000 publications dealing with the cardiovascular risk of cyclooxygenase inhibitors and it can be concluded that the use of both selective and non-selective inhibitors is accompanied by a substantial cardiovascular risk (e.g. infarction, thromboembolic events, cardiac insufficiency and possibly stroke). As these pharmaceuticals, including paracetamol and acetylsalicylic acid, belong to the most used medications and safer alternatives are still lacking it will be the aim in the future to keep the risk connected with the therapy with these drugs limited despite the fact that the aging population will demand an increased consumption of analgesics. Choosing the right substance (e.g. selective versus non-selective, fast elimination versus slow elimination) and the correct dosage, i.e. the lowest possible dosing range, will help to keep the risk within tolerable limits. In addition biomarkers have emerged which will allow the identification of patients with a high risk of cardiovascular hepatic and gastrointestinal side effects.
authors.affiliation: Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Deutschland. Kay.Brune@pharmakologie.med.uni-erlangen.de
authors.forename: K
authors.initials: K
authors.lastname: Brune
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D019317:Evidence-Based Medicine / Q000639:trends*; D006801:Humans; D012216:Rheumatic Diseases / Q000150:complications / Q000188:drug therapy*
chemical_list: D016861:Cyclooxygenase Inhibitors